David Hallal
Chairman at SCHOLAR ROCK HOLDING CORPORATION
Net worth: 8 M $ as of 2024-03-30
Profile
Mr. David L. Hallal is a Chairman & Chief Executive Officer at AlloVir, Inc., a Chairman at iTeos Therapeutics SA, a Chairman at iTeos Therapeutics, Inc., a Lead Independent Director at Seer, Inc. (California), a Chairman & Chief Executive Officer at ElevateBio LLC, a Chairman at Scholar Rock, Inc. and a Chairman at Scholar Rock Holding Corp. He is on the Board of Directors at Seer, Inc. (California) and Pharmaceutical Research & Manufacturers of America. Mr. Hallal was previously employed as a Chief Executive Officer & Director by Alexion Pharmaceuticals, Inc., a Vice President-Sales by (OSI) Eyetech, a Head-Sales by Biogen Idec, Inc., a Director-Southeast Oncology Sales by Amgen, Inc., and a Director-National Sales by Eyetech Pharmaceuticals, Inc. He received his undergraduate degree from the University of New Hampshire.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2023-06-20 | 290,595 ( 0.37% ) | 5 M $ | 2024-03-30 | |
ALLOVIR INC
2.60% | 2023-05-10 | 2,967,780 ( 2.60% ) | 2 M $ | 2024-03-30 |
SEER, INC. CLASS A
0.49% | 2023-06-13 | 296,950 ( 0.49% ) | 564 205 $ | 2024-03-30 |
ITEOS THERAPEUTICS, INC.
-.--% | 2023-06-12 | 0 ( -.--% ) | - $ | 2024-03-30 |
David Hallal active positions
Companies | Position | Start |
---|---|---|
SCHOLAR ROCK HOLDING CORPORATION | Chairman | 2017-06-30 |
SEER, INC. | Director/Board Member | 2018-01-31 |
ITEOS THERAPEUTICS, INC. | Chairman | 2018-05-31 |
ALLOVIR, INC. | Chairman | 2018-08-31 |
Pharmaceutical Research & Manufacturers of America
Pharmaceutical Research & Manufacturers of America Pharmaceuticals: MajorHealth Technology Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC. | Director/Board Member | - |
Scholar Rock, Inc.
Scholar Rock, Inc. BiotechnologyHealth Technology Scholar Rock, Inc. operates as a biotechnology company. It focuses on discovering and developing a novel class of biologic therapies that target supracellular activation of growth factors in the disease microenvironment. The company was founded by Timothy Springer and Leonard Zon and is headquartered in Cambridge, MA. | Chairman | 2017-07-05 |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Chairman | 2018-06-26 |
ElevateBio LLC
ElevateBio LLC BiotechnologyHealth Technology ElevateBio LLC is a biotechnology holding company, which creates and operates a broad portfolio of cell and gene therapy companies. It builds single and multi-product companies by providing scientific founders with bench-to-bedside capabilities including scientists, manufacturing facilities, drug developers, and commercial expertise. The company was founded by David L. Hallal, Vikas Sinha, and Mitchell H. Finer and is headquartered in Cambridge, MA. | Chief Executive Officer | 2017-11-30 |
LifeEDIT Therapeutics, Inc.
LifeEDIT Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of ElevateBio LLC, LifeEDIT Therapeutics, Inc. is a next-generation genome editing private company that has built a highly innovative platform with one of the world's largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The company offers gene editing tools with higher fidelity, novel functionality, reduced immune response risk, and easier delivery. LifeEDIT has a large and diverse library of RGNs, including type II and type V systems that encompass knock-out and knock-in capabilities, transcriptional regulation, and base editing when coupled with one of their proprietary deaminases. The company's nuclease collection has a broad range of protospacer adjacent motifs (PAMs), offering unprecedented access to genomes. LifeEDIT is headquartered in Morrisville, NC. The CEO of the company is Mitchell H. Finer. LifeEDIT Therapeutics was acquired by ElevateBio LLC from AgBiome Delta LLC on October 27, 2021. | Director/Board Member | - |
Former positions of David Hallal
Companies | Position | End |
---|---|---|
░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░░░░ | ░░░░░ ░ ░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░ | ░░░░░ ░ ░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░ | ░░░░░ ░ ░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░ | ░░░░░ ░ ░░░░░░░░░ | - |
Training of David Hallal
University of New Hampshire | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 6 |
---|---|
AMGEN INC. | Health Technology |
BIOGEN INC. | Health Technology |
ALLOVIR, INC. | Health Technology |
SEER, INC. | Health Technology |
SCHOLAR ROCK HOLDING CORPORATION | Health Technology |
ITEOS THERAPEUTICS, INC. | Health Technology |
Private companies | 8 |
---|---|
Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Oldtech, Inc.
Oldtech, Inc. BiotechnologyHealth Technology Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York. | Health Technology |
(OSI) Eyetech
(OSI) Eyetech Medical SpecialtiesHealth Technology OSI Eyetech provides medical services. It is specializee in the development and commercialization of therapeutics to treat diseases of the eye. The company is headquartered in New York City, NY. | Health Technology |
Pharmaceutical Research & Manufacturers of America
Pharmaceutical Research & Manufacturers of America Pharmaceuticals: MajorHealth Technology Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC. | Health Technology |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Health Technology |
Scholar Rock, Inc.
Scholar Rock, Inc. BiotechnologyHealth Technology Scholar Rock, Inc. operates as a biotechnology company. It focuses on discovering and developing a novel class of biologic therapies that target supracellular activation of growth factors in the disease microenvironment. The company was founded by Timothy Springer and Leonard Zon and is headquartered in Cambridge, MA. | Health Technology |
ElevateBio LLC
ElevateBio LLC BiotechnologyHealth Technology ElevateBio LLC is a biotechnology holding company, which creates and operates a broad portfolio of cell and gene therapy companies. It builds single and multi-product companies by providing scientific founders with bench-to-bedside capabilities including scientists, manufacturing facilities, drug developers, and commercial expertise. The company was founded by David L. Hallal, Vikas Sinha, and Mitchell H. Finer and is headquartered in Cambridge, MA. | Health Technology |
LifeEDIT Therapeutics, Inc.
LifeEDIT Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of ElevateBio LLC, LifeEDIT Therapeutics, Inc. is a next-generation genome editing private company that has built a highly innovative platform with one of the world's largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The company offers gene editing tools with higher fidelity, novel functionality, reduced immune response risk, and easier delivery. LifeEDIT has a large and diverse library of RGNs, including type II and type V systems that encompass knock-out and knock-in capabilities, transcriptional regulation, and base editing when coupled with one of their proprietary deaminases. The company's nuclease collection has a broad range of protospacer adjacent motifs (PAMs), offering unprecedented access to genomes. LifeEDIT is headquartered in Morrisville, NC. The CEO of the company is Mitchell H. Finer. LifeEDIT Therapeutics was acquired by ElevateBio LLC from AgBiome Delta LLC on October 27, 2021. | Commercial Services |
- Stock Market
- Insiders
- David Hallal